Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

232results about "Polypeptide with enzyme fusion" patented technology

Synthetic 5'UTRs, Expression Vectors, and Methods for Increasing Transgene Expression

ActiveUS20100293625A1Increase transgene expressionImprove stabilityVectorsSugar derivativesReticulum cellIntein
The present invention provides synthetic 5′UTRs comprising a first polynucleotide fragment and a second polynucleotide fragment, wherein the first polynucleotide fragment comprises at least one splice site of a first eukaryotic gene, the second polynucleotide fragment comprises at least a portion of 5′ untranslated region of a second eukaryotic gene, and the first polynucleotide fragment is located 5′ of the second polynucleotide fragment. In one embodiment, the first polynucleotide fragment comprises the second intron of a sarcoplasmic / endoplasmic reticulum calcium ATPase gene and the second polynucleotide fragment comprises at least a portion of the 5′ untranslated region (5′UTR) of a eukaryotic casein gene. The synthetic 5′UTRs are useful for increasing the expression of a transgene when positioned between a promoter and a transgene within an expression vector. The present invention also provides vectors comprising synthetic 5′UTRs and methods for increasing the expression of a transgene using synthetic 5′UTRs.
Owner:PRECIGEN INC

Targeted therapeutic proteins

Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.
Owner:BIOMARIN PHARMA INC

Covalent tethering of functional groups to proteins and substrates therefor

ActiveUS20060024808A1Rapidly and efficiently loaded into and washedStable rateMethine/polymethine dyesBacteriaAmino acid substitutionTethering
A mutant hydrolase optionally fused to a protein of interest is provided. The mutant hydrolase is capable of forming a bond with a substrate for the corresponding nonmutant (wild-type) hydrolase which is more stable than the bond formed between the wild-type hydrolase and the substrate and has at least two amino acid substitutions relative to the wild-type hydrolase. Substrates for hydrolases comprising one or more functional groups are also provided, as well as methods of using the mutant hydrolase and the substrates of the invention. Also provided is a fusion protein capable of forming a stable bond with a substrate and cells which express the fusion protein.
Owner:PROMEGA CORP

Methods for treating spinal muscular atrophy

The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA.
Owner:PTC THERAPEUTICS INC

Multimeric forms of members of the steroid/thyroid superfamily of receptors

In accordance with the present invention, it has been discovered that various members of the steroid / thyroid superfamily of receptors can interact to form multimeric species comprising a complex of more than one receptor. Accordingly, the interaction of a first receptor species with a second receptor species modulates the ability of the first receptor species to trans-activate transcription of genes maintained under hormone expression control in the presence of the cognate ligand for said first receptor.
Owner:SALK INST FOR BIOLOGICAL STUDIES

Optimized messenger RNA

InactiveUS20080076174A1Broaden applicationEliminates issue concerning patient complianceFactor VIISugar derivativesMessenger RNAComputational biology
The present invention is directed to a synthetic nucleic acid sequence which encodes a protein wherein at least one non-common codon or less-common codon is replaced by a common codon. The synthetic nucleic acid sequence can include a continuous stretch of at least 90 codons all of which are common codons.
Owner:SHIRE HUMAN GENETIC THERAPIES INC

Targeted therapeutic proteins

Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor. Nucleic acids, cells, and methods relating to the practice of the invention are also provided.
Owner:BIOMARIN PHARMA INC

Infectious, chimeric hepatitis C virus, methods of producing the same and methods of use thereof

The present invention provides infectious recombinant Hepatitis C Viruses (HCV), and vectors, cells and animals comprising the same. The present invention provides methods of producing infectious recombinant HCV, and their use in identifying anti-HCV therapeutic agents, as well as sequences of HCV associated with HCV pathogenesis.
Owner:THE ROCKEFELLER UNIV

Single-Molecule-Format Probe And Utilization Thereof

InactiveUS20090269781A1High sensorial efficiencySuppresses background enzyme activityAnimal cellsSugar derivativesCrystallographyProtein target
A single-chain probe of the present invention for detecting a ligand, comprises: a ligand binding protein for binding the ligand; a recognition protein for recognizing that the ligand is bound by the ligand binding protein; and C— and N-terminal fragments, generated by dissecting an enzyme, between the ligand binding protein and the recognition protein, wherein a carboxy terminal end of the C-terminal fragment is located upstream of an amino terminal end of the N-terminal fragment, and the C— and N-terminal fragments vary the enzyme activity via complementation in case where the recognition protein recognizes that the ligand is bound by the ligand binding protein. This makes it possible to achieve detection of a target protein-specific ligand using the single chain with a high efficiency.
Owner:NAT INST OF ADVANCED IND SCI & TECH

Process for production of recombinant proteins as a soluble form

A target protein is prepared as soluble protein using a recombinant protein expression system. An expression vector is used that includes (1) an expression-inducible promoter sequence; (2) a first coding sequence including a polynucleotide coding for a polypeptide that is represented by the formula (Z)n; and (3) a second coding sequence that includes a polynucleotide that codes for a target protein. A method of producing the target protein is also used that includes expressing protein using this expression vector.
Owner:JNC CORP

Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes

Methods for preparing cell lines that contain artificial chromosomes, methods for preparation of artificial chromosomes, methods for purification of artificial chromosomes, methods for targeted insertion of heterologous DNA into artificial chromosomes, and methods for delivery of the chromosomes to selected cells and tissues are provided. Also provided are cell lines for use in the methods, and cell lines and chromosomes produced by the methods. Methods for use of the artificial chromosomes are also provided.
Owner:THE BIOLOGICAL RES CENT OF THE HUNGARIAN ACAD OF SCI +1

Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes

Methods for preparing cell lines that contain artificial chromosomes, methods for preparation of artificial chromosomes, methods for purification of artificial chromosomes, methods for targeted insertion of heterologous DNA into artificial chromosomes, methods for amplification of nucleic acids and methods for delivery of the chromosomes to selected cells and tissues are provided. Also provided are cell lines for use in the methods, and cell lines and chromosomes produced by the methods. Methods for use of the artificial chromosomes are also provided.
Owner:HADLACZKY GYULA +1

Tetracycline-regulated transcriptional activator fusion proteins

A method for regulating expression of a tet operator-linked gene in a cell of a subject is disclosed. In one embodiment, the method involves introducing into the cell a nucleic acid molecule encoding a tetracycline-controllable transactivator (tTA), the tTA comprising a Tet repressor operably linked to a polypeptide which directly or indirectly activates transcription in eucaryotic cells; and modulating the concentration of a tetracycline, or analogue thereof, in the subject. Alternatively, in another embodiment, the method involves obtaining the cell from the subject, introducing into the cell a first nucleic acid molecule which operatively links a gene to at least one tet operator sequence, introducing into the cell a second nucleic acid molecule encoding a tTA, to form a modified cell, administering the modified cell to the subject, and modulating the concentration of a tetracycline, or analogue thereof, in the subject. The first and second nucleic acid molecule can be within a single molecule (e.g., in the same vector) or on separate molecules.
Owner:TET SYST

Human immunodeficiency virus (HIV) nucleotide sequences

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and / or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to prepare antibodies, where both the polypeptides and antibodies may be employed as diagnostic reagents or in therapy, e.g., vaccines and passive immunization. The sequences provide detection of the viral infectious agents associated with the indicated syndromes and can be used for expression of antigenic polypeptides.
Owner:NOVARTIS VACCINES & DIAGNOSTICS INC

Polymer enzyme-antibody and preparation method thereof

The invention belongs to the technical field of medical detection, and especially relates to a polymer enzyme linked antibody and a preparation method thereof. The polymer enzyme is prepared by carrying out polymerization between DVS activated enzyme and PAMAN Dendrimer series branched organic molecular carriers. The provided method overcomes the main shortages of a conventional polymer enzyme linking method that takes chain-like polymer (glucan or polypeptide) as the carriers; moreover, the volume of polymer enzyme is greatly reduced; the density of enzyme labeling on antibody is increased, and the number of enzymes that is linked to the secondary antibody in a unit volume is largely increased. The produced polymer enzyme linked secondary antibody has the higher sensitivity and stability, compared with those of conventional enzyme labeled secondary antibody.
Owner:XIAMEN TALENT BIOMEDICAL TECH CO LTD

Modified Foot-And-Mouth Disease Virus 3C Proteases, Compositions And Methods Thereof

This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC OF HOMELAND SECURITY

Methods and compositions for secretion of heterologous polypeptides

The instant invention discloses the unexpected result that mutant signal sequences with reduced translational strength provided essentially complete processing and high levels of expression of a polypeptide of interest as compared to wild type signal sequences, and that many mammalian polypeptides require a narrow range of translation levels to achieve maximum secretion. A set of signal sequence vectors provides a range of translational strengths for optimizing expression of a polypeptide of interest.
Owner:GENENTECH INC

Novel coronavirus vaccine and application thereof

The invention relates to a novel coronavirus vaccine and application thereof, in particular to a truncated Spike protein, a fusion protein containing the truncated Spike protein, a nucleic acid molecule containing a nucleotide sequence encoding the truncated Spike protein or the fusion protein, and a vector and a host cell containing the nucleic acid molecule. The invention further relates to a pharmaceutical composition containing the truncated Spike protein, fusion protein, nucleic acid molecule or vector.
Owner:BEIJING NORTHLAND BIOTECH

Engineering of leader peptides for the secretion of recombinant proteins in bacteria

InactiveUS7419783B2Increased green fluorescent protein fluorescenceImproved protein exportBacteriaPeptide/protein ingredientsBacteroidesADAMTS Proteins
The present invention provides methods of isolating of leader peptides capable of directing export of heterologous proteins from the bacterial cytoplasm. The methods rely on the screening of libraries of putative leader peptides or of leader peptide mutants for sequences that allow rapid export and thus can rescue a short-lived reporter protein from degradation in the cytoplasm. The mutant leader peptides identified herein are shown to confer significantly higher steady state levels of export not only for short-lived reporter protein but also for other stable, long-lived proteins. These leader peptides can be used to direct or enhance protein secretion. The present invention further discloses methods for the export of cytoplasmically folded protein via the Tat pathway. Proteins having disulfide bonds are first folded within the cytoplasm in suitable oxidizing mutant strains. Such cytoplasmically pre-folded proteins containing disulfide bonds are then exported via the Tat pathway.
Owner:RES DEVMENT FOUND

Multicolor bioluminescent visualization probe set, or single-molecule-format multicolor bioluminescent visualization probe

The present invention provides ligand detection means capable of exhibiting two-dimensional information (wavelength and intensity of luminescent signal) responding to multiple signals triggered by a ligand via a target protein, while taking advantage of the merit of the single-molecule-format bioluminescent probe.The present invention could provide a luminescent probe set which is comprised of a fusion protein comprising a ligand recognition protein and a molecular recognition domain to which the ligand recognition protein bind upon conformational change, wherein the fusion protein is sandwiched between split Lighting Enzyme fragments, the probe set can emit multiple luminescence by utilizing Lighting Enzymes emitting lights with multiple wavelength, wherein these multiple components can be tandemly arranged by using C-terminal fragment of the Lighting Enzyme.By using a living cell line transfected with gene of multicolor luminescent probe set or single-molecule-format multicolor bioluminescent probe, it becomes possible to distinguish and detect bioactivity level of a target ligand in a complex context of the living cell two-dimensionally (wavelength versus intensity) in multi colors, and to quantitatively evaluate multiple effects (anticancer and carcinogenesis actions, agonist and antagonist) of a ligand represented by a drug at once by two-dimensional information of different colors in short time.
Owner:NAT INST OF ADVANCED IND SCI & TECH

Lambdoid bacteriophage vectors for expression of foreign proteins

Lambdoid phage comprising a matrix of proteins encapsulating a genome encoding first and second polypeptides of an autogenously assembling receptor and a receptor comprised of the first and second polypeptides surface-integrated into the matrix via a lambdoid phage tail protein matrix anchor domain fused to at least one of the polypeptides.
Owner:THE SCRIPPS RES INST

Recombinant receptor binding protein and recombinant receptor protein for detecting new coronavirus neutralizing antibody

The invention belongs to the field of biological medicines, and relates to a recombinant receptor binding protein and a recombinant receptor protein for detecting a new coronavirus neutralizing antibody, in particular to the recombinant receptor binding protein, the recombinant receptor protein, a nucleic acid molecule, a recombinant expression vector, a recombinant host cell, a reagent composition, a kit and application. The recombinant receptor binding protein is an RBD trimer protein, the RBD trimer protein has an optimized spatial structure and higher immunogenicity, the recombinant receptor protein is an ACE2 dimer protein, the ACE2 dimer protein has a natural protein conformation capable of simulating ACE2, after the recombinant receptor binding protein and the recombinant receptor protein are combined, the new coronavirus neutralizing antibody can be detected through the principle of enzyme linked immunosorbent assay, the sensitivity, specificity and stability are remarkably improved, and the requirement for tracking detection of the new coronavirus neutralizing antibody on the market can be greatly met.
Owner:SUZHOU CUREMED BIOMEDICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products